0LC7.LSE Syros Pharmaceuticals, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is 0LC7.LSE undervalued?

Graham number

The Graham number of Syros Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Syros Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for Syros Pharmaceuticals, Inc. yet.

Syros Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patie…

Full company profile